Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Review

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Authors: Luca Pompili, Carlo Leonetti, Annamaria Biroccio, Erica Salvati

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Telomeres are specialized nucleoprotein structures responsible for protecting chromosome ends in order to prevent the loss of genomic information. Telomere maintenance is required for achieving immortality by neoplastic cells. While most cancer cells rely on telomerase re-activation for linear chromosome maintenance and sustained proliferation, a significant population of cancers (10–15%) employs telomerase-independent strategies, collectively referred to as Alternative Lengthening of Telomeres (ALT). ALT mechanisms involve different types of homology-directed telomere recombination and synthesis. These processes are facilitated by loss of the ATRX or DAXX chromatin-remodeling factors and by abnormalities of the telomere nucleoprotein architecture. Although the functional consequences of telomerase and ALT up-regulation are similar in that they both prevent overall telomere shortening in tumors, these telomere maintenance mechanisms (TMMs) differ in several aspects which may account for their differential prognostic significance and response to therapy in various tumor types. Therefore, reliable methods for detecting telomerase activity and ALT are likely to become an important pre-requisite for the use of treatments targeting one or other of these mechanisms. However, the question whether ALT presence can confer sensitivity to rationally designed anti-cancer therapies is still open. Here we review the latest discoveries in terms of mechanisms of ALT activation and maintenance in human tumors, methods for ALT identification in cell lines and human tissues and biomarkers validation. Then, original results on sensitivity to rational based pre-clinical and clinical anti-tumor drugs in ALT vs hTERT positive cells will be presented.
Literature
1.
2.
de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100–10.CrossRefPubMed
3.
Erdel F, Kratz K, Willcox S, Griffith JD, Greene EC, de Lange T. Telomere recognition and assembly mechanism of mammalian Shelterin. Cell Rep. 2017;18:41–53.CrossRefPubMedPubMedCentral
4.
Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72–6.CrossRefPubMed
5.
Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–8.CrossRefPubMed
6.
MacNeil DE, Bensoussan HJ, Autexier C. Telomerase regulation from beginning to the end. Genes (Basel). 2016;7
7.
Zeng S, Liu L, Sun Y, et al. Telomerase-mediated telomere elongation from human blastocysts to embryonic stem cells. J Cell Sci. 2014;127:752–62.CrossRefPubMed
8.
Rivera T, Haggblom C, Cosconati S, Karlseder J. A balance between elongation and trimming regulates telomere stability in stem cells. Nat Struct Mol Biol. 2017;24:30–9.CrossRefPubMed
9.
Liu L, Bailey SM, Okuka M, et al. Telomere lengthening early in development. Nat Cell Biol. 2007;9:1436–41.CrossRefPubMed
10.
Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997;3:1271–4.CrossRefPubMed
11.
Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14:4240–8.PubMedPubMedCentral
12.
Min J, Wright WE, Shay JW. Alternative lengthening of telomeres can be maintained by preferential elongation of lagging strands. Nucleic Acids Res. 2017;45:2615–28.CrossRefPubMedPubMedCentral
13.
Slatter TL, Tan X, Yuen YC, et al. The alternative lengthening of telomeres pathway may operate in non-neoplastic human cells. J Pathol. 2012;226:509–18.CrossRefPubMed
14.
Novakovic B, Napier CE, Vryer R, et al. DNA methylation mediated up-regulation of TERRA non-coding RNA is coincident with elongated telomeres in the human placenta. Mol Hum Reprod. 2016;22:791–9.CrossRefPubMed
15.
Pickett HA, Reddel RR. Molecular mechanisms of activity and derepression of alternative lengthening of telomeres. Nat Struct Mol Biol. 2015;22:875–80.CrossRefPubMed
16.
Costa A, Daidone MG, Daprai L, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006;66:8918–24.CrossRefPubMed
17.
Jeyapalan JN, Mendez-Bermudez A, Zaffaroni N, Dubrova YE, Royle NJ. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies. Int J Cancer. 2008;122:2414–21.CrossRefPubMed
18.
Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003;361:836–8.CrossRefPubMed
19.
Gupta J, Han LP, Wang P, Gallie BL, Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst. 1996;88:1152–7.CrossRefPubMed
20.
Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003;63:1759–63.PubMed
21.
Dagg RA, Pickett HA, Neumann AA, et al. Extensive proliferation of human cancer cells with ever-shorter telomeres. Cell Rep. 2017;19:2544–56.CrossRefPubMed
22.
Chen Q, Ijpma A, Greider CW. Two survivor pathways that allow growth in the absence of telomerase are generated by distinct telomere recombination events. Mol Cell Biol. 2001;21:1819–27.CrossRefPubMedPubMedCentral
23.
Teng SC, Chang J, McCowan B, Zakian VA. Telomerase-independent lengthening of yeast telomeres occurs by an abrupt Rad50p-dependent, Rif-inhibited recombinational process. Mol Cell. 2000;6:947–52.CrossRefPubMed
24.
Lydeard JR, Jain S, Yamaguchi M, Haber JE. Break-induced replication and telomerase-independent telomere maintenance require Pol32. Nature. 2007;448:820–3.CrossRefPubMed
25.
Kreilmeier T, Sampl S, Deloria AJ, et al. Alternative lengthening of telomeres does exist in various canine sarcomas. Mol Carcinog. 2017;56:923–35.CrossRefPubMed
26.
Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179:1608–15.CrossRefPubMedPubMedCentral
27.
Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 2010;584:3800–11.CrossRefPubMed
28.
Serakinci N, Hoare SF, Kassem M, Atkinson SP, Keith WN. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen Med. 2006;1:125–31.CrossRefPubMed
29.
Koelsche C, Renner M, Hartmann W, et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res. 2014;33:33.CrossRefPubMedPubMedCentral
30.
Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175–9.PubMed
31.
Nittis T, Guittat L, Stewart SA. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection? Biochimie. 2008;90:5–12.CrossRefPubMed
32.
Wilson FR, Ho A, Walker JR, Zhu XD. Cdk-dependent phosphorylation regulates TRF1 recruitment to PML bodies and promotes C-circle production in ALT cells. J Cell Sci. 2016;129:2559–72.CrossRefPubMed
33.
Ho A, Wilson FR, Peragine SL, Jeyanthan K, Mitchell TR, Zhu XD. TRF1 phosphorylation on T271 modulates telomerase-dependent telomere length maintenance as well as the formation of ALT-associated PML bodies. Sci Rep. 2016;6:36913.CrossRefPubMedPubMedCentral
34.
Perrem K, Bryan TM, Englezou A, Hackl T, Moy EL, Reddel RR. Repression of an alternative mechanism for lengthening of telomeres in somatic cell hybrids. Oncogene. 1999;18:3383–90.CrossRefPubMed
35.
36.
Lovejoy CA, Li W, Reisenweber S, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet. 2012;8:e1002772.CrossRefPubMedPubMedCentral
37.
Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482:226–31.CrossRefPubMed
38.
Xue Y, Gibbons R, Yan Z, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A. 2003;100:10635–40.CrossRefPubMedPubMedCentral
39.
Clynes D, Jelinska C, Xella B, et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun. 2015;6:7538.CrossRefPubMedPubMedCentral
40.
Nguyen DT, Voon HPJ, Xella B, et al. The chromatin remodelling factor ATRX suppresses R-loops in transcribed telomeric repeats. EMBO Rep. 2017;18:914–28.CrossRefPubMed
41.
Leung JW, Ghosal G, Wang W, et al. Alpha thalassemia/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress. J Biol Chem. 2013;288:6342–50.CrossRefPubMedPubMedCentral
42.
Huh MS, Price O'Dea T, Ouazia D, et al. Compromised genomic integrity impedes muscle growth after Atrx inactivation. J Clin Invest 2012;122: 4412–4423.CrossRefPubMedPubMedCentral
43.
Koschmann C, Calinescu AA, Nunez FJ, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016;8: 328ra328.
44.
45.
Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum Mol Genet. 2005;14 Spec No. 2: R191–R196.
46.
Della-Maria J, Zhou Y, Tsai MS, et al. Human Mre11/human Rad50/Nbs1 and DNA ligase IIIalpha/XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. J Biol Chem. 2011;286:33845–53.CrossRefPubMedPubMedCentral
47.
Naderlinger E, Holzmann K. Epigenetic regulation of telomere maintenance for therapeutic interventions in gliomas. Genes (Basel). 2017;8
48.
Cimino-Reale G, Gandellini P, Santambrogio F, Recagni M, Zaffaroni N, Folini M. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. J Hematol Oncol. 2017;10:140.CrossRefPubMedPubMedCentral
49.
Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends. Science. 2007;318:798–801.CrossRefPubMed
50.
51.
Graf M, Bonetti D, Lockhart A, et al. Telomere length determines TERRA and R-loop regulation through the cell cycle. Cell. 2017;170:72–85. e14CrossRefPubMed
52.
Chu HP, Cifuentes-Rojas C, Kesner B, et al. TERRA RNA antagonizes ATRX and protects telomeres. Cell. 2017;170:86–101. e116CrossRefPubMed
53.
Balk B, Maicher A, Dees M, et al. Telomeric RNA-DNA hybrids affect telomere-length dynamics and senescence. Nat Struct Mol Biol. 2013;20:1199–205.CrossRefPubMed
54.
Arora R, Lee Y, Wischnewski H, Brun CM, Schwarz T, Azzalin CM. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat Commun. 2014;5:5220.CrossRefPubMedPubMedCentral
55.
TY Y, Kao YW, Lin JJ. Telomeric transcripts stimulate telomere recombination to suppress senescence in cells lacking telomerase. Proc Natl Acad Sci U S A. 2014;111:3377–82.CrossRef
56.
Dilley RL, Verma P, Cho NW, Winters HD, Wondisford AR, Greenberg RA. Break-induced telomere synthesis underlies alternative telomere maintenance. Nature. 2016;539:54–8.CrossRefPubMedPubMedCentral
57.
Sobinoff AP, Allen JA, Neumann AA, et al. BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres. EMBO J. 2017;
58.
Min J, Wright WE, Shay JW. Alternative lengthening of telomeres mediated by mitotic DNA synthesis engages break-induced replication processes. Mol Cell Biol. 2017;37
59.
Chen YJ, Hakin-Smith V, Teo M, et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 2006;66:6473–6.CrossRefPubMed
60.
Pan X, Drosopoulos WC, Sethi L, Madireddy A, Schildkraut CL, Zhang D. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci U S A. 2017;114:E5940–9.CrossRefPubMed
61.
Cesare AJ, Griffith JD. Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops. Mol Cell Biol. 2004;24:9948–57.CrossRefPubMedPubMedCentral
62.
Pickett HA, Reddel RR. The role of telomere trimming in normal telomere length dynamics. Cell Cycle. 2012;11:1309–15.CrossRefPubMed
63.
Henson JD, Lau LM, Koch S, Martin la Rotta N, Dagg RA, Reddel RR. The C-circle assay for alternative-lengthening-of-telomeres activity. Methods. 2017;114:74–84.CrossRefPubMed
64.
Matsuo T, Sugita T, Shimose S, et al. Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas. J Exp Clin Cancer Res. 2008;27:73.CrossRefPubMedPubMedCentral
65.
VandenBussche CJ, Allison DB, Graham MK, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer. 2017;125:544–51.PubMed
66.
Liau JY, Tsai JH, Yang CY, et al. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas. Hum Pathol. 2015;46:1360–6.CrossRefPubMed
67.
Liau JY, Tsai JH, Jeng YM, Lee JC, Hsu HH, Yang CY. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am J Surg Pathol. 2015;39:236–44.CrossRefPubMed
68.
Fernandez-Marcelo T, Gomez A, Pascua I, et al. Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status. J Exp Clin Cancer Res. 2015;34:78.CrossRefPubMedPubMedCentral
69.
Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M. Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone. Anticancer Res. 2010;30:4959–62.PubMed
70.
Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer. 2010;10:254.CrossRefPubMedPubMedCentral
71.
Lee YK, Park NH, Lee H. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma. Int J Gynecol Cancer. 2012;22:434–41.CrossRefPubMed
72.
McDonald KL, McDonnell J, Muntoni A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J Neuropathol Exp Neurol. 2010;69:729–36.CrossRefPubMed
73.
Dorris K, Sobo M, Onar-Thomas A, et al. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas. J Neuro-Oncol. 2014;117:67–76.CrossRef
74.
Mangerel J, Price A, Castelo-Branco P, et al. Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. Acta Neuropathol. 2014;128:853–62.CrossRefPubMed
75.
Zhang Y, Cai L, Wei RX, Hu H, Jin W, Zhu XB. Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines. Oncol Lett. 2011;2:1327–32.PubMedPubMedCentral
76.
Bidzinska J, Cimino-Reale G, Zaffaroni N, Folini M. G-Quadruplex structures in the human genome as novel therapeutic targets. Molecules. 2013;18:12368–95.CrossRefPubMed
77.
Gowan SM, Heald R, Stevens MF, Kelland LR. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol. 2001;60:981–8.PubMed
78.
Iachettini S, Stevens MF, Frigerio M, et al. On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. J Exp Clin Cancer Res. 2013;32:68.CrossRefPubMedPubMedCentral
79.
Rizzo A, Iachettini S, Zizza P, et al. Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. J Exp Clin Cancer Res. 2014;33:81.CrossRefPubMedPubMedCentral
80.
Salvati E, Leonetti C, Rizzo A, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest. 2007;117:3236–47.CrossRefPubMedPubMedCentral
81.
Rizzo A, Salvati E, Porru M, et al. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res. 2009;37:5353–64.CrossRefPubMedPubMedCentral
82.
Biroccio A, Porru M, Rizzo A, et al. DNA damage persistence as determinant of tumor sensitivity to the combination of topo I inhibitors and telomere-targeting agents. Clin Cancer Res. 2011;17:2227–36.CrossRefPubMed
83.
Berardinelli F, Coluzzi E, Sgura A, Antoccia A. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models. Mutat Res. 2017;773:204–19.CrossRefPubMed
84.
Porru M, Zizza P, Franceschin M, Leonetti C, Biroccio A. EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochim Biophys Acta. 2017;1861:1362–70.CrossRefPubMed
85.
Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived xenografts: a relevant preclinical model for drug development. J Exp Clin Cancer Res. 2016;35:189.CrossRefPubMedPubMedCentral
86.
Xu H, Di Antonio M, McKinney S, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun. 2017;8:14432.CrossRefPubMedPubMedCentral
87.
88.
D'Incalci M, Galmarini CM. A Review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9:2157–63.CrossRefPubMed
89.
90.
Gocha AR, Nuovo G, Iwenofu OH, Groden J. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Am J Pathol. 2013;182:41–8.CrossRefPubMedPubMedCentral
91.
Greco C, Zupi G. Biological features and in vitro chemosensitivity of a new model of human melanoma. Anticancer Res. 1987;7:839–44.PubMed
92.
Berardinelli F, Nieri D, Sgura A, Tanzarella C, Antoccia A. Telomere loss, not average telomere length, confers radiosensitivity to TK6-irradiated cells. Mutat Res. 2012;740:13–20.CrossRefPubMed
93.
Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 1997;25:2595–7.CrossRefPubMedPubMedCentral
94.
Kimura M, Stone RC, Hunt SC, et al. Measurement of telomere length by the southern blot analysis of terminal restriction fragment lengths. Nat Protoc. 2010;5:1596–607.CrossRefPubMed
Metadata
Title
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Authors
Luca Pompili
Carlo Leonetti
Annamaria Biroccio
Erica Salvati
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0657-3

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue

Research

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

Research

Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway

Research

Heat shock factor 1 inhibits the mitochondrial apoptosis pathway by regulating second mitochondria-derived activator of caspase to promote pancreatic tumorigenesis

Research

High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods

Research

Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death

Research

Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits